Dongyao Pharmaceutical-B (1875.HK): Park Hin-ting is growing rapidly, and the ADC CDMO business has obvious advantages
國元國際Mar 20 00:00
Dongyao Pharmaceutical-B (1875.HK): BIOTECH's gorgeous transformation ADC CDMO has great potential
安信國際Jun 13, 2023 00:00
Research Report Nuggets 丨 Guoyuan International: Dongyao Pharmaceutical and Intelligent Nuclear Biology Cooperate into the Field of Nuclear Medicine, and CDMO Space Is Vast
Gelonghui FinanceApr 26, 2023 12:06
Dongyao Pharmaceutical-B (1875.HK): Park Shin-ting's rapid sales volume, rapid expansion of CDMO business
國元國際Aug 18, 2022 00:00
Dongyao Pharmaceutical-B (1875.HK): Heavy products have begun to be commercialized, and the CDMO business is developing rapidly
國元國際Apr 13, 2022 00:00
Dongyao Pharmaceutical: Bevacizumab accelerates commercialization, CDMO's performance contribution is outstanding
安信國際Feb 9, 2022 16:35
Dongyao Pharmaceutical (1875.HK): End of coverage
浦銀國際Jan 26, 2022 00:00
Dongyao Pharmaceutical-B (1875.HK): Gradual improvement in revenue structure+CDMO/CMO business transformation aims to drive rapid growth in performance
第一上海Aug 19, 2021 00:00
Dongyao Pharmaceutical (1875.HK): CDMO performed brilliantly, TAA013+ phase III clinical trials progressed steadily
浦銀國際Aug 16, 2021 00:00
Dongyao Pharmaceutical-B (1875.HK): ADC drug development is in clinical phase 3, and the prospects are worth looking forward to
安信國際Apr 9, 2021 00:00
Dongyao Pharmaceutical-B (1875.HK): New drugs have entered the harvest period, CDMO business is being vigorously promoted
國元國際Mar 29, 2021 00:00
Dongyao Pharmaceutical (01875.HK): stepping into the harvest period, CDMO/CMO business goes to a new level.
興業證券Mar 26, 2021 00:00
Dongyao Pharmaceutical (1875.HK): A number of drugs will be marketed during the year, TAA013 phase III clinical trials are progressing steadily
浦銀國際Mar 25, 2021 00:00
Dongyao Pharmaceutical (1875.HK): TAB014 clinical phase III IND application approved by FDA
浦銀國際Feb 2, 2021 00:00
Dongyao Pharmaceutical-B (1875.HK): New drug development has entered the harvest period, ADC's new drug advantage is obvious
國元國際Dec 30, 2020 00:00
Dongyao Pharmaceutical-B (01875.HK): resource integration, orderly development, continuous optimization of management structure
第一上海Oct 30, 2020 00:00
Dongyao Pharmaceutical (1875.HK): research and development projects steadily promote product harvest
興業證券Aug 21, 2020 00:00
东曜药业(01875.HK)1H20业绩:ADC药物进入III期临床 生物类似药申报延误
浦銀國際Aug 18, 2020 00:00
Dongyao Pharmaceutical-B (01875.HK): Deepening the field of antitumor therapy and building a leading ADC technology platform in China has great potential
第一上海Aug 5, 2020 00:00
东曜药业-B(01875.HK)新股资讯
中泰國際Oct 29, 2019 00:00
No Data
No Data